Search research articles
Contact Us
Filters
Showing results (51-60 of 141) with videos related to
Page
of 15
Sort By:
BMJ Oncology
|
January 31, 2025
Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN Renal 101 trial
Matthew Tucker, Yu-Wei Chen, Martin H Voss, et al.
Clinical Genitourinary Cancer
|
May 1, 2019
Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes
Yasser Ged, Ying-Bei Chen, Andrea Knezevic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2018
PTEN Expression, Not Mutation Status in <i>TSC1, TSC2</i>, or <i>mTOR</i>, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial
Martin H Voss, David Chen, Albert Reising, et al.
World Journal of Urology
|
March 29, 2021
A qualitative framework of non-selection factors for cytoreductive nephrectomy
Andrew W Silagy, Kyrollis Attalla, Renzo G Dinatale, et al.
The Oncologist
|
April 8, 2015
The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience
Richard M Bambury, David J Benjamin, Joshua L Chaim, et al.
JAMA Ophthalmology
|
September 2, 2021
Clinical and Morphologic Characteristics of Fibroblast Growth Factor Receptor Inhibitor-Associated Retinopathy
Jasmine H Francis, James J Harding, Alison M Schram, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2016
The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma
Martin H Voss, Rupal S Bhatt, Elizabeth R Plimack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 21, 2021
A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors
James J Harding, Melinda Telli, Pamela Munster, et al.
Cancer
|
July 21, 2021
Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma
Andrew W Silagy, Ritesh R Kotecha, Stanley Weng, et al.
The American Journal of Surgical Pathology
|
January 21, 2014
Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry
Ying-Bei Chen, A Rose Brannon, Antoun Toubaji, et al.
Page
of 15
Search research articles
Search
Showing results (51-60 of 141) with videos related to
Sort By:
Page
of 15
BMJ Oncology
|
January 31, 2025
Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN Renal 101 trial
Matthew Tucker, Yu-Wei Chen, Martin H Voss, et al.
Clinical Genitourinary Cancer
|
May 1, 2019
Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes
Yasser Ged, Ying-Bei Chen, Andrea Knezevic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2018
PTEN Expression, Not Mutation Status in <i>TSC1, TSC2</i>, or <i>mTOR</i>, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial
Martin H Voss, David Chen, Albert Reising, et al.
World Journal of Urology
|
March 29, 2021
A qualitative framework of non-selection factors for cytoreductive nephrectomy
Andrew W Silagy, Kyrollis Attalla, Renzo G Dinatale, et al.
The Oncologist
|
April 8, 2015
The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience
Richard M Bambury, David J Benjamin, Joshua L Chaim, et al.
JAMA Ophthalmology
|
September 2, 2021
Clinical and Morphologic Characteristics of Fibroblast Growth Factor Receptor Inhibitor-Associated Retinopathy
Jasmine H Francis, James J Harding, Alison M Schram, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2016
The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma
Martin H Voss, Rupal S Bhatt, Elizabeth R Plimack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 21, 2021
A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors
James J Harding, Melinda Telli, Pamela Munster, et al.
Cancer
|
July 21, 2021
Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma
Andrew W Silagy, Ritesh R Kotecha, Stanley Weng, et al.
The American Journal of Surgical Pathology
|
January 21, 2014
Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry
Ying-Bei Chen, A Rose Brannon, Antoun Toubaji, et al.
Page
of 15